Aurobindo Pharma gets USFDA warning letter for Hyderabad facility over poor manufacturing practices
New Delhi: Drugmaker, Aurobindo Pharma has announced that the company has received a warning letter from the US Food and Drug Administration (USFDA) for its Hyderabad-based Unit I, an API (active pharmaceutical ingredient) manufacturing facility.
The action follows the recent inspection of the facility by the USFDA in August 2021, the company said in a regulatory filing.
"The company believes that this will not impact the existing business from this facility," it noted.
The drugmaker stated that it will be engaging with the regulator and is fully committed to resolving the issue at the earliest.
The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe, it noted.
Read also: Aurobindo Pharma gets USFDA OAI status for API facility in Hyderabad
"A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations," reports PTI.
The letter identifies the violation, such as poor manufacturing practices, problems with claims for what a product can do, or incorrect directions for use.
The letter also makes clear that the company must correct the problem and provides directions and a timeframe of its plans for correction.
FDA then checks to ensure that the company's corrections are adequate.
Read also: Unichem, Aurobindo Pharma recall Topiramate, Carvedilol respectively in US
Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 155 countries.
The company has 27 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA.
